3D scaffolds in breast cancer research

Biomaterials

Volumn 81, Issue , 2016, Pages 135-156

  Rijal, Girdhari ^a   Li, Weimin ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

3D scaffold; Breast tumor; Cell ECM interaction; Drug delivery; Extracellular matrix; Signaling

Indexed keywords

BLOOD VESSELS; CELLS; CYTOLOGY; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; ENZYME ACTIVITY; SCAFFOLDS (BIOLOGY); SIGNALING; TUMORS;

3-D SCAFFOLDS; ALTERNATIVE SYSTEMS; BREAST TUMOR; CANCER CELL GROWTH; CELL-CELL INTERACTION; EXTRACELLULAR MATRICES; INTENSIVE RESEARCH; THERAPEUTIC EFFICACY;

CELL SIGNALING;

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR SCAFFOLD; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RAS PROTEIN; RHO KINASE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BIOCOMPATIBILITY; BIODEGRADABILITY; BREAST CANCER; CANCER CELL; CANCER RESEARCH; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYDROGEL; MACROPHAGE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE CULTURE; TUMOR MICROENVIRONMENT; BREAST TUMOR; CELL COMMUNICATION; CHEMISTRY; DRUG EFFECTS; FEMALE; MEDICAL RESEARCH; PATHOLOGY; TISSUE SCAFFOLD;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CELL COMMUNICATION; FEMALE; HUMANS; SIGNAL TRANSDUCTION; TISSUE SCAFFOLDS;

EID: 84953227804     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.12.016     Document Type: Review

References (237)

1. Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010, 123:4195-4200.
2. DeQuach J.A., Mezzano V., Miglani A., Lange S., Keller G.M., Sheikh F., et al. Simple and high yielding method for preparing tissue specific extracellular matrix coatings for cell culture. PloS One 2010, 5:e13039.
3. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 2005, 5:675-688.
4. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer 2007, 7:659-672.
5. Sung K.E., Su G., Pehlke C., Trier S.M., Eliceiri K.W., Keely P.J., et al. Control of 3-dimensional collagen matrix polymerization for reproducible human mammary fibroblast cell culture in microfluidic devices. Biomaterials 2009, 30:4833-4841.
6. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
7. Carreau A., El Hafny-Rahbi B., Matejuk A., Grillon C., Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J. Cell Mol. Med. 2011, 15:1239-1253.
8. Rodbell M. The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 1980, 284:17-22.
9. Cirri P., Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 2011, 1:482-497.
10. Schmeichel K.L., Bissell M.J. Modeling tissue-specific signaling and organ function in three dimensions. J. Cell Sci. 2003, 116:2377-2388.
11. Wang H., Lacoche S., Huang L., Xue B., Muthuswamy S.K. Rotational motion during three-dimensional morphogenesis of mammary epithelial acini relates to laminin matrix assembly. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:163-168.
12. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
13. Ong S.M., Zhao Z., Arooz T., Zhao D., Zhang S., Du T., et al. Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 2010, 31:1180-1190.
14. Timmins N.E., Nielsen L.K. Generation of multicellular tumor spheroids by the hanging-drop method. Methods Mol. Med. 2007, 140:141-151.
15. Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J. Vis. Exp. 2011, 51:e2720.
16. Jaganathan H., Gage J., Leonard F., Srinivasan S., Souza G.R., Dave B., et al. Three-dimensional In Vitro co-culture model of breast tumor using magnetic levitation. Sci. Rep. 2014, 4:6468.
17. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
18. Pati F., Jang J., Ha D.H., Won Kim S., Rhie J.W., Shim J.H., et al. Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink. Nat. Commun. 2014, 5:3935.
19. Paszek M.J., Weaver V.M. The tension mounts: mechanics meets morphogenesis and malignancy. J. Mammary Gland. Biol. Neoplasia 2004, 9:325-342.
20. Fischer R.S., Myers K.A., Gardel M.L., Waterman C.M. Stiffness-controlled three-dimensional extracellular matrices for high-resolution imaging of cell behavior. Nat. Protoc. 2012, 7:2056-2066.
21. Lee K.Y., Mooney D.J. Hydrogels for tissue engineering. Chem. Rev. 2001, 101:1869-1879.
22. Samuel M.S., Lopez J.I., McGhee E.J., Croft D.R., Strachan D., Timpson P., et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011, 19:776-791.
23. Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010, 22:697-706.
24. O'Brien F.J., Harley B.A., Yannas I.V., Gibson L. Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds. Biomaterials 2004, 25:1077-1086.
25. Kim Y.J., Bae H.I., Kwon O.K., Choi M.S. Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test. Int. J. Biol. Macromol. 2009, 45:65-71.
26. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
27. Chen L., Xiao Z., Meng Y., Zhao Y., Han J., Su G., et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 2012, 33:1437-1444.
28. Lu W.D., Zhang L., Wu C.L., Liu Z.G., Lei G.Y., Liu J., et al. Development of an acellular tumor extracellular matrix as a three-dimensional scaffold for tumor engineering. PloS One 2014, 9:e103672.
29. Velling T., Risteli J., Wennerberg K., Mosher D.F., Johansson S. Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1. J. Biol. Chem. 2002, 277:37377-37381.
30. Nam J.M., Onodera Y., Bissell M.J., Park C.C. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res. 2010, 70:5238-5248.
31. Roman J., LaChance R.M., Broekelmann T.J., Kennedy C.J., Wayner E.A., Carter W.G., et al. The fibronectin receptor is organized by extracellular matrix fibronectin: implications for oncogenic transformation and for cell recognition of fibronectin matrices. J. Cell Biol. 1989, 108:2529-2543.
32. Joly P., Duda G.N., Schone M., Welzel P.B., Freudenberg U., Werner C., et al. Geometry-driven cell organization determines tissue growths in scaffold pores: consequences for fibronectin organization. PloS One 2013, 8:e73545.
33. Sales V.L., Engelmayr G.C., Johnson J.A., Gao J., Wang Y., Sacks M.S., et al. Protein precoating of elastomeric tissue-engineering scaffolds increased cellularity, enhanced extracellular matrix protein production, and differentially regulated the phenotypes of circulating endothelial progenitor cells. Circulation 2007, 116:I55-I63.
34. Campos D.M., Gritsch K., Salles V., Attik G.N., Grosgogeat B. Surface entrapment of fibronectin on electrospun PLGA scaffolds for periodontal tissue engineering. Biores Open Access. 2014, 3:117-126.
35. Kapoor A., Sen S. Synergistic modulation of cellular contractility by mixed extracellular matrices. Int. J. Cell Biol. 2012, 2012:471591.
36. Stoffels J.M., Zhao C., Baron W. Fibronectin in tissue regeneration: timely disassembly of the scaffold is necessary to complete the build. cellular and molecular life sciences. CMLS 2013, 70:4243-4253.
37. Muzzarelli R.A., Biagini G., Bellardini M., Simonelli L., Castaldini C., Fratto G. Osteoconduction exerted by methylpyrrolidinone chitosan used in dental surgery. Biomaterials 1993, 14:39-43.
38. Dhiman H.K., Ray A.R., Panda A.K. Characterization and evaluation of chitosan matrix for in vitro growth of MCF-7 breast cancer cell lines. Biomaterials 2004, 25:5147-5154.
39. Talukdar S., Mandal M., Hutmacher D.W., Russell P.J., Soekmadji C., Kundu S.C. Engineered silk fibroin protein 3D matrices for in vitro tumor model. Biomaterials 2011, 32:2149-2159.
40. Gobin A.S., Froude V.E., Mathur A.B. Structural and mechanical characteristics of silk fibroin and chitosan blend scaffolds for tissue regeneration. J. Biomed. Mater. Res. A 2005, 74:465-473.
41. Kievit F.M., Florczyk S.J., Leung M.C., Wang K., Wu J.D., Silber J.R., et al. Proliferation and enrichment of CD133(+) glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds. Biomaterials 2014, 35:9137-9143.
42. Levinger I., Ventura Y., Vago R. Life is three dimensional-as in vitro cancer cultures should be. Adv. Cancer Res. 2014, 121:383-414.
43. Yang X., Sarvestani S.K., Moeinzadeh S., He X., Jabbari E. Effect of CD44 binding peptide conjugated to an engineered inert matrix on maintenance of breast cancer stem cells and tumorsphere formation. PloS One 2013, 8:e59147.
44. Florczyk S.J., Wang K., Jana S., Wood D.L., Sytsma S.K., Sham J.G., et al. Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. Biomaterials 2013, 34:10143-10150.
45. Campbell J.J., Davidenko N., Caffarel M.M., Cameron R.E., Watson C.J. A multifunctional 3D co-culture system for studies of mammary tissue morphogenesis and stem cell biology. PloS One 2011, 6:e25661.
46. Feng S., Duan X., Lo P.K., Liu S., Liu X., Chen H., et al. Expansion of breast cancer stem cells with fibrous scaffolds. Integr. Biol. (Camb) 2013, 5:768-777.
47. Qiu P., Qu X., Brackett D.J., Lerner M.R., Li D., Mao C. Silica-based branched hollow microfibers as a biomimetic extracellular matrix for promoting tumor cell growth in vitro and in vivo. Adv. Mater. 2013, 25:2492-2496.
48. Long T.J., Sprenger C.C., Plymate S.R., Ratner B.D. Prostate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape. Biomaterials 2014, 35:8164-8174.
49. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., et al. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
50. Girard Y.K., Wang C., Ravi S., Howell M.C., Mallela J., Alibrahim M., et al. A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development. PloS One 2013, 8:e75345.
51. Pradhan S., Chaudhury C.S., Lipke E.A. Dual-phase, surface tension-based fabrication method for generation of tumor millibeads. Langmuir 2014, 30:3817-3825.
52. Tibbitt M.W., Anseth K.S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol. Bioeng. 2009, 103:655-663.
53. Paralkar V.M., Vukicevic S., Reddi A.H. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev. Biol. 1991, 143:303-308.
54. Mi K., Xing Z. CD44(+)/CD24(-) breast cancer cells exhibit phenotypic reversion in three-dimensional self-assembling peptide RADA16 nanofiber scaffold. Int. J. Nanomedicine 2015, 10:3043-3053.
55. Weiss M.S., Bernabe B.P., Shikanov A., Bluver D.A., Mui M.D., Shin S., et al. The impact of adhesion peptides within hydrogels on the phenotype and signaling of normal and cancerous mammary epithelial cells. Biomaterials 2012, 33:3548-3559.
56. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 2005, 167:475-488.
57. Kirshner J., Chen C.J., Liu P., Huang J., Shively J.E. CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:521-526.
58. Muthuswamy S.K., Li D., Lelievre S., Bissell M.J., Brugge J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 2001, 3:785-792.
59. Debnath J., Mills K.R., Collins N.L., Reginato M.J., Muthuswamy S.K., Brugge J.S. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002, 111:29-40.
60. Chen J., Miller E.M., Gallo K.A. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 2010, 29:4399-4411.
61. Montanez-Sauri S.I., Sung K.E., Berthier E., Beebe D.J. Enabling screening in 3D microenvironments: probing matrix and stromal effects on the morphology and proliferation of T47D breast carcinoma cells. Integr. Biol. (Camb) 2013, 5:631-640.
62. Wang F., Hansen R.K., Radisky D., Yoneda T., Barcellos-Hoff M.H., Petersen O.W., et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J. Natl. Cancer Inst. 2002, 94:1494-1503.
63. Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015, 11:630-644.
64. Vidi P.A., Bissell M.J., Lelievre S.A. Three-dimensional culture of human breast epithelial cells: the how and the why. Methods Mol. Biol. 2013, 945:193-219.
65. Aranda V., Haire T., Nolan M.E., Calarco J.P., Rosenberg A.Z., Fawcett J.P., et al. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat. Cell Biol. 2006, 8:1235-1245.
66. Ivers L.P., Cummings B., Owolabi F., Welzel K., Klinger R., Saitoh S., et al. Dynamic and influential interaction of cancer cells with normal epithelial cells in 3D culture. Cancer Cell Int. 2014, 14:108.
67. Sadlonova A., Novak Z., Johnson M.R., Bowe D.B., Gault S.R., Page G.P., et al. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res. 2005, 7:R46-R59.
68. Tanaka M., Abe T., Hara Y. Roles of focal adhesions and fibronectin-mediated cohesion in proliferation of confluent fibroblasts. J. Cell Physiol. 2009, 219:194-201.
69. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
70. Camp J.T., Elloumi F., Roman-Perez E., Rein J., Stewart D.A., Harrell J.C., et al. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol. Cancer Res. 2011, 9:3-13.
71. Oerlecke I., Bauer E., Dittmer A., Leyh B., Dittmer J. Cyclic AMP enhances TGFbeta responses of breast cancer cells by upregulating TGFbeta receptor I expression. PloS One 2013, 8:e54261.
72. Chandrasekaran S., Geng Y., DeLouise L.A., King M.R. Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines. Biomaterials 2012, 33:9037-9048.
73. Sung K.E., Su X., Berthier E., Pehlke C., Friedl A., Beebe D.J. Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PloS One 2013, 8:e76373.
74. Olsen C.J., Moreira J., Lukanidin E.M., Ambartsumian N.S. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer 2010, 10:444.
75. Su G., Sung K.E., Beebe D.J., Friedl A. Functional screen of paracrine signals in breast carcinoma fibroblasts. PloS One 2012, 7:e46685.
76. Sasser A.K., Mundy B.L., Smith K.M., Studebaker A.W., Axel A.E., Haidet A.M., et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett. 2007, 254:255-264.
77. Li L., Lu Y. Optimizing a 3D culture system to study the interaction between epithelial breast cancer and its surrounding fibroblasts. J. Cancer 2011, 2:458-466.
78. Howes A.L., Richardson R.D., Finlay D., Vuori K. 3-dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems. PloS One 2014, 9:e108283.
79. Mohamed M.M. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway. Cell Commun. Signal. 2012, 10:3.
80. Gradl D., Kuhl M., Wedlich D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol. Cell. Biol. 1999, 19:5576-5587.
81. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42:717-727.
82. Stewart D.A., Yang Y., Makowski L., Troester M.A. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol. Cancer Res. 2012, 10:727-738.
83. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
84. Vlaicu P., Mertins P., Mayr T., Widschwendter P., Ataseven B., Hogel B., et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 2013, 13:197.
85. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64:7022-7029.
86. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 2005, 175:1197-1205.
87. Hagemann T., Robinson S.C., Schulz M., Trumper L., Balkwill F.R., Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25:1543-1549.
88. Shree T., Olson O.C., Elie B.T., Kester J.C., Garfall A.L., Simpson K., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25:2465-2479.
89. Lin E.Y., Li J.F., Gnatovskiy L., Deng Y., Zhu L., Grzesik D.A., et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66:11238-11246.
90. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
91. Chwalek K., Bray L.J., Werner C. Tissue-engineered 3D tumor angiogenesis models: potential technologies for anti-cancer drug discovery. Adv. Drug Deliv. Rev. 2014, 79-80:30-39.
92. Correa de Sampaio P., Auslaender D., Krubasik D., Failla A.V., Skepper J.N., Murphy G., et al. A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PloS One 2012, 7:e30753.
93. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
94. Buchanan C.F., Szot C.S., Wilson T.D., Akman S., Metheny-Barlow L.J., Robertson J.L., et al. Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro. J. Cell Biochem. 2012, 113:1142-1151.
95. Sigurdsson V., Hilmarsdottir B., Sigmundsdottir H., Fridriksdottir A.J., Ringner M., Villadsen R., et al. Endothelial induced EMT in breast epithelial cells with stem cell properties. PloS One 2011, 6:e23833.
96. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998, 95:365-377.
97. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442.
98. Harunaga J.S., Yamada K.M. Cell-matrix adhesions in 3D. Matrix Biol. 2011, 30:363-368.
99. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374.
100. Geiger B., Yamada K.M. Molecular architecture and function of matrix adhesions. Cold Spring Harb. Perspect. Biol. 2011, 3.
101. Hartsock A., Nelson W.J. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim. Biophys. Acta 2008, 1778:660-669.
102. Burridge K., Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu. Rev. Cell Dev. Biol. 1996, 12:463-518.
103. Acs G., Lawton T.J., Rebbeck T.R., LiVolsi V.A., Zhang P.J. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am. J. Clin. Pathol. 2001, 115:85-98.
104. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
105. Martin T.A., Mansel R.E., Jiang W.G. Loss of occludin leads to the progression of human breast cancer. Int. J. Mol. Med. 2010, 26:723-734.
106. Jovanovic B., Beeler J.S., Pickup M.W., Chytil A., Gorska A.E., Ashby W.J., et al. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Res. 2014, 16:R69.
107. Choi Y.P., Lee J.H., Gao M.Q., Kim B.G., Kang S., Kim S.H., et al. Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models. Int. J. Cancer 2014, 135:2024-2033.
108. Schaffner F., Ray A.M., Dontenwill M. Integrin alpha5beta1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers (Basel) 2013, 5:27-47.
109. Scales T.M., Jayo A., Obara B., Holt M.R., Hotchin N.A., Berditchevski F., et al. alpha3beta1 integrins regulate CD151 complex assembly and membrane dynamics in carcinoma cells within 3D environments. Oncogene 2013, 32:3965-3979.
110. Borghi N., Lowndes M., Maruthamuthu V., Gardel M.L., Nelson W.J. Regulation of cell motile behavior by crosstalk between cadherin- and integrin-mediated adhesions. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13324-13329.
111. Canel M., Serrels A., Frame M.C., Brunton V.G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J. Cell Sci. 2013, 126:393-401.
112. Paszek M.J., DuFort C.C., Rossier O., Bainer R., Mouw J.K., Godula K., et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 2014, 511:319-325.
113. Zschenker O., Streichert T., Hehlgans S., Cordes N. Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PloS One 2012, 7:e34279.
114. Du J., Che P.L., Wang Z.Y., Aich U., Yarema K.J. Designing a binding interface for control of cancer cell adhesion via 3D topography and metabolic oligosaccharide engineering. Biomaterials 2011, 32:5427-5437.
115. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119:1420-1428.
116. Troussard A.A., Costello P., Yoganathan T.N., Kumagai S., Roskelley C.D., Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 2000, 19:5444-5452.
117. Filipenko N.R., Attwell S., Roskelley C., Dedhar S. Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene 2005, 24:5837-5849.
118. Imanishi Y., Hu B., Jarzynka M.J., Guo P., Elishaev E., Bar-Joseph I., et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 2007, 67:4254-4263.
119. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
120. Yamaguchi H., Wyckoff J., Condeelis J. Cell migration in tumors. Curr. Opin. Cell Biol. 2005, 17:559-564.
121. Bravo-Cordero J.J., Magalhaes M.A., Eddy R.J., Hodgson L., Condeelis J. Functions of cofilin in cell locomotion and invasion. Nat. Rev. Mol. Cell Biol. 2013, 14:405-415.
122. Bernstein B.W., Bamburg J.R. ADF/cofilin: a functional node in cell biology. Trends Cell Biol. 2010, 20:187-195.
123. Yu X., Zech T., McDonald L., Gonzalez E.G., Li A., Macpherson I., et al. N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J. Cell Biol. 2012, 199:527-544.
124. Garcia E., Machesky L.M., Jones G.E., Anton I.M. WIP is necessary for matrix invasion by breast cancer cells. Eur. J. Cell Biol. 2014, 93:413-423.
125. Poincloux R., Collin O., Lizarraga F., Romao M., Debray M., Piel M., et al. Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1943-1948.
126. Charras G., Paluch E. Blebs lead the way: how to migrate without lamellipodia. Nat. Rev. Mol. Cell Biol. 2008, 9:730-736.
127. Daubon T., Rochelle T., Bourmeyster N., Genot E. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells. Eur. J. Cell Biol. 2012, 91:978-987.
128. Wang W., Wyckoff J.B., Frohlich V.C., Oleynikov Y., Huttelmaier S., Zavadil J., et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 2002, 62:6278-6288.
129. Wolf K., Friedl P. Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol. 2011, 21:736-744.
130. Even-Ram S., Yamada K.M. Cell migration in 3D matrix. Curr. Opin. Cell Biol. 2005, 17:524-532.
131. Haessler U., Teo J.C., Foretay D., Renaud P., Swartz M.A. Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. Integr. Biol. (Camb) 2012, 4:401-409.
132. Okochi M., Matsumura T., Honda H. Magnetic force-based cell patterning for evaluation of the effect of stromal fibroblasts on invasive capacity in 3D cultures. Biosens. Bioelectron. 2013, 42:300-307.
133. Wolf K., Te Lindert M., Krause M., Alexander S., Te Riet J., Willis A.L., et al. Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J. Cell Biol. 2013, 201:1069-1084.
134. Funamoto K., Zervantonakis I.K., Liu Y., Ochs C.J., Kim C., Kamm R.D. A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment. Lab. Chip 2012, 12:4855-4863.
135. Koch T.M., Munster S., Bonakdar N., Butler J.P., Fabry B. 3D traction forces in cancer cell invasion. PloS One 2012, 7:e33476.
136. Bordeleau F., Tang L.N., Reinhart-King C.A. Topographical guidance of 3D tumor cell migration at an interface of collagen densities. Phys. Biol. 2013, 10:065004.
137. Zaman M.H., Trapani L.M., Sieminski A.L., Mackellar D., Gong H., Kamm R.D., et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10889-10894.
138. Depypere H.T., Bolca S., Bracke M., Delanghe J., Comhaire F., Blondeel P. The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue. Maturitas 2015, 81:42-45.
139. Ricketts D., Turnbull L., Ryall G., Bakhshi R., Rawson N.S., Gazet J.C., et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res. 1991, 51:1817-1822.
140. Macedo L.F., Sabnis G.J., Goloubeva O.G., Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008, 68:3516-3522.
141. Barone I., Brusco L., Fuqua S.A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clinical cancer research. Off. J. Am. Assoc. Cancer Res. 2010, 16:2702-2708.
142. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 2009, 20:477-482.
143. Zhu Y., Bond J., Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2237-2242.
144. Thomas P., Pang Y., Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRalpha) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology 2014, 155:1107-1119.
145. Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature 2015, 523:313-317.
146. Hefti M.M., Hu R., Knoblauch N.W., Collins L.C., Haibe-Kains B., Tamimi R.M., et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013, 15:R68.
147. Olivotto I.A., Truong P.T., Speers C.H., Bernstein V., Allan S.J., Kelly S.J., et al. Time to stop progesterone receptor testing in breast cancer management. J. Clin. Oncol. 2004, 22:1769-1770.
148. Bernoux A., de Cremoux P., Laine-Bidron C., Martin E.C., Asselain B., Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie breast cancer study group. Breast Cancer Res. Treat. 1998, 49:219-225.
149. Hynes N.E., Watson C.J. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a003186.
150. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
151. Lucs A.V., Muller W.J., Muthuswamy S.K. Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 2010, 29:174-187.
152. Chang J., Nicolau M.M., Cox T.R., Wetterskog D., Martens J.W., Barker H.E., et al. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Breast Cancer Res. 2013, 15:R67.
153. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
154. Davis W.J., Lehmann P.Z., Li W. Nuclear PI3K signaling in cell growth and tumorigenesis. Front. Cell Dev. Biol. 2015, 3:24.
155. Yuan J., Liu M., Yang L., Tu G., Zhu Q., Chen M., et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res. 2015, 17:69.
156. Pylayeva Y., Gillen K.M., Gerald W., Beggs H.E., Reichardt L.F., Giancotti F.G. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J. Clin. Investig. 2009, 119:252-266.
157. Long W., Yi P., Amazit L., LaMarca H.L., Ashcroft F., Kumar R., et al. SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol. Cell 2010, 37:321-332.
158. Stover D.R., Becker M., Liebetanz J., Lydon N.B. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J. Biol. Chem. 1995, 270:15591-15597.
159. Xia H., Nho R.S., Kahm J., Kleidon J., Henke C.A. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J. Biol. Chem. 2004, 279:33024-33034.
160. Castello-Cros R., Khan D.R., Simons J., Valianou M., Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009, 9:94.
161. Mizushima H., Wang X., Miyamoto S., Mekada E. Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures. J. Cell Sci. 2009, 122:4277-4286.
162. Weigelt B., Lo A.T., Park C.C., Gray J.W., Bissell M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 2010, 122:35-43.
163. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Investig. 2008, 118:3065-3074.
164. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J., Ibrahim Y.H., Chandarlapaty S., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557.
165. Yu C.F., Liu Z.X., Cantley L.G. ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J. Biol. Chem. 2002, 277:19382-19388.
166. Aksamitiene E., Kiyatkin A., Kholodenko B.N. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem. Soc. Trans. 2012, 40:139-146.
167. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
168. Zheng H., Tian W., Yan H., Yue L., Zhang Y., Han F., et al. Rotary culture promotes the proliferation of MCF-7 cells encapsulated in three-dimensional collagen-alginate hydrogels via activation of the ERK1/2-MAPK pathway. Biomed. Mater. 2012, 7:015003.
169. Maschler S., Grunert S., Danielopol A., Beug H., Wirl G. Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells. Oncogene 2004, 23:3622-3633.
170. Taherian A., Li X., Liu Y., Haas T.A. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 2011, 11:293.
171. Arias-Romero L.E., Chernoff J. p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target?. Small GTPases 2010, 1:124-128.
172. Higuchi M., Onishi K., Kikuchi C., Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell Biol. 2008, 10:1356-1364.
173. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13:781-792.
174. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 2003, 116:217-224.
175. Wipff P.J., Rifkin D.B., Meister J.J., Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 2007, 179:1311-1323.
176. Shi M., Zhu J., Wang R., Chen X., Mi L., Walz T., et al. Latent TGF-beta structure and activation. Nature 2011, 474:343-349.
177. Leight J.L., Wozniak M.A., Chen S., Lynch M.L., Chen C.S. Matrix rigidity regulates a switch between TGF-beta1-induced apoptosis and epithelial-mesenchymal transition. Mol. Biol. Cell. 2012, 23:781-791.
178. Gomes L.R., Terra L.F., Wailemann R.A., Labriola L., Sogayar M.C. TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 2012, 12:26.
179. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999, 13:804-816.
180. Sundqvist A., Zieba A., Vasilaki E., Herrera Hidalgo C., Soderberg O., Koinuma D., et al. Specific interactions between Smad proteins and AP-1 components determine TGFbeta-induced breast cancer cell invasion. Oncogene 2013, 32:3606-3615.
181. Freytag J., Wilkins-Port C.E., Higgins C.E., Carlson J.A., Noel A., Foidart J.M., et al. PAI-1 regulates the invasive phenotype in human cutaneous squamous cell carcinoma. J. Oncol. 2009, 2009:963209.
182. Liu S., Xu S.W., Kennedy L., Pala D., Chen Y., Eastwood M., et al. FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol. Biol. Cell. 2007, 18:2169-2178.
183. Epstein Shochet G., Tartakover-Matalon S., Drucker L., Pasmanik-Chor M., Pomeranz M., Fishman A., et al. Placenta-breast cancer cell interactions promote cancer cell epithelial mesenchymal transition via TGFbeta/JNK pathway. Clin. Exp. Metastasis 2014, 31:961-975.
184. Lee M.S., Kim S., Kim B.G., Won C., Nam S.H., Kang S., et al. Snail1 induced in breast cancer cells in 3D collagen I gel environment suppresses cortactin and impairs effective invadopodia formation. Biochim. Biophys. Acta 2014, 1843:2037-2054.
185. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15:178-196.
186. Schwartz M. Rho signalling at a glance. J. Cell Sci. 2004, 117:5457-5458.
187. Amano M., Nakayama M., Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskelet. Hob. 2010, 67:545-554.
188. Pickup M.W., Mouw J.K., Weaver V.M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014, 15:1243-1253.
189. Larsen M., Artym V.V., Green J.A., Yamada K.M. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell Biol. 2006, 18:463-471.
190. Guilluy C., Swaminathan V., Garcia-Mata R., O'Brien E.T., Superfine R., Burridge K. The Rho GEFs LARG and GEF-H1 regulate the mechanical response to force on integrins. Nat. Cell Biol. 2011, 13:722-727.
191. Herrema H., Czajkowska D., Theard D., van der Wouden J.M., Kalicharan D., Zolghadr B., et al. Rho kinase, myosin-II, and p42/44 MAPK control extracellular matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells. Mol. Biol. Cell. 2006, 17:3291-3303.
192. Wozniak M.A., Desai R., Solski P.A., Der C.J., Keely P.J. ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J. Cell Biol. 2003, 163:583-595.
193. Provenzano P.P., Inman D.R., Eliceiri K.W., Trier S.M., Keely P.J. Contact guidance mediated three-dimensional cell migration is regulated by Rho/ROCK-dependent matrix reorganization. Biophys. J. 2008, 95:5374-5384.
194. Schafer Z.T., Brugge J.S. IL-6 involvement in epithelial cancers. J. Clin. Investig. 2007, 117:3660-3663.
195. Furuta S., Jiang X., Gu B., Cheng E., Chen P.L., Lee W.H. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9176-9181.
196. Ouchi T., Lee S.W., Ouchi M., Aaronson S.A., Horvath C.M. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5208-5213.
197. Gao B., Shen X., Kunos G., Meng Q., Goldberg I.D., Rosen E.M., et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. 2001, 488:179-184.
198. Leslie K., Gao S.P., Berishaj M., Podsypanina K., Ho H., Ivashkiv L., et al. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res. 2010, 12:R80.
199. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
200. Weber A., Borghouts C., Brendel C., Moriggl R., Delis N., Brill B., et al. Stat5 exerts distinct, vital functions in the cytoplasm and nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia cells. Cancers (Basel) 2015, 7:503-537.
201. Sultan A.S., Xie J., LeBaron M.J., Ealley E.L., Nevalainen M.T., Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005, 24:746-760.
202. Tan S.H., Nevalainen M.T. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr. Relat. Cancer 2008, 15:367-390.
203. Wendt M.K., Balanis N., Carlin C.R., Schiemann W.P. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT 2014, 3:e28975.
204. Zammarchi F., de Stanchina E., Bournazou E., Supakorndej T., Martires K., Riedel E., et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17779-17784.
205. Bharadwaj U., Kasembeli M.M., Eckols T.K., Kolosov M., Lang P., Christensen K., et al. Monoclonal antibodies specific for STAT3beta reveal its contribution to constitutive STAT3 phosphorylation in breast cancer. Cancers (Basel) 2014, 6:2012-2034.
206. Hakanson M., Textor M., Charnley M. Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer. Integr. Biol. (Camb) 2011, 3:31-38.
207. Deiss F., Mazzeo A., Hong E., Ingber D.E., Derda R., Whitesides G.M. Platform for high-throughput testing of the effect of soluble compounds on 3D cell cultures. Anal. Chem. 2013, 85:8085-8094.
208. Polo M.L., Arnoni M.V., Riggio M., Wargon V., Lanari C., Novaro V. Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PloS One 2010, 5:e10786.
209. Xie P., Williams D.S., Atilla-Gokcumen G.E., Milk L., Xiao M., Smalley K.S., et al. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 2008, 3:305-316.
210. Imamura Y., Mukohara T., Shimono Y., Funakoshi Y., Chayahara N., Toyoda M., et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol. Rep. 2015, 33:1837-1843.
211. Mitra M., Mohanty C., Harilal A., Maheswari U.K., Sahoo S.K., Krishnakumar S. A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol. Vis. 2012, 18:1361-1378.
212. Mi K., Wang G., Liu Z., Feng Z., Huang B., Zhao X. Influence of a self-assembling peptide, RADA16, compared with collagen I and matrigel on the malignant phenotype of human breast-cancer cells in 3D cultures and in vivo. Macromol. Biosci. 2009, 9:437-443.
213. Kim D.H., Provenzano P.P., Smith C.L., Levchenko A. Matrix nanotopography as a regulator of cell function. J. Cell Biol. 2012, 197:351-360.
214. Christopherson G.T., Song H., Mao H.Q. The influence of fiber diameter of electrospun substrates on neural stem cell differentiation and proliferation. Biomaterials 2009, 30:556-564.
215. Abrams G.A., Murphy C.J., Wang Z.Y., Nealey P.F., Bjorling D.E. Ultrastructural basement membrane topography of the bladder epithelium. Urol. Res. 2003, 31:341-346.
216. Ekert J.E., Johnson K., Strake B., Pardinas J., Jarantow S., Perkinson R., et al. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro-implication for drug development. PloS One 2014, 9:e92248.
217. Yamaguchi Y., Deng D., Sato Y., Hou Y.T., Watanabe R., Sasaki K., et al. Silicate fiber-based 3D cell culture system for anticancer drug screening. Anticancer Res. 2013, 33:5301-5309.
218. Liu L.J., Zhang J., Xiao Z.F., Dai B., Sun M.Y., Chen L., et al. Three-dimensional collagen scaffold enhances the human adenoid cystic carcinoma cancer stem cell and epithelial-mesenchymal transition properties. J. Biomed. Mater Res. B Appl. Biomater. 2014, 102:772-780.
219. Garg T., Singh O., Arora S., Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 2012, 29:1-63.
220. Ki C.S., Shih H., Lin C.C. Effect of 3D matrix compositions on the efficacy of EGFR inhibition in pancreatic ductal adenocarcinoma cells. Biomacromolecules 2013, 14:3017-3026.
221. Huang H., Ding Y., Sun X.S., Nguyen T.A. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. PloS One 2013, 8:e59482.
222. Tian R., Chen J., Niu R. The development of low-molecular weight hydrogels for applications in cancer therapy. Nanoscale 2014, 6:3474-3482.
223. Shin C.S., Kwak B., Han B., Park K. Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug. Mol. Pharm. 2013, 10:2167-2175.
224. Hwang H., Park J., Shin C., Do Y., Cho Y.K. Three dimensional multicellular co-cultures and anti-cancer drug assays in rapid prototyped multilevel microfluidic devices. Biomed. Microdevices 2013, 15:627-634.
225. Kretlow J.D., Klouda L., Mikos A.G. Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv. drug Deliv. Rev. 2007, 59:263-273.
226. Weadock K.S., Miller E.J., Bellincampi L.D., Zawadsky J.P., Dunn M.G. Physical crosslinking of collagen fibers: comparison of ultraviolet irradiation and dehydrothermal treatment. J. Biomed. Mater. Res. 1995, 29:1373-1379.
227. Rowland C.R., Lennon D.P., Caplan A.I., Guilak F. The effects of crosslinking of scaffolds engineered from cartilage ECM on the chondrogenic differentiation of MSCs. Biomaterials 2013, 34:5802-5812.
228. Chen Y.Y., Wu H.C., Sun J.S., Dong G.C., Wang T.W. Injectable and thermoresponsive self-assembled nanocomposite hydrogel for long-term anticancer drug delivery. Langmuir 2013, 29:3721-3729.
229. Appel E.A., Tibbitt M.W., Webber M.J., Mattix B.A., Veiseh O., Langer R. Self-assembled hydrogels utilizing polymer-nanoparticle interactions. Nat. Commun. 2015, 6:6295.
230. Lee A.L.Z., Ng V.W.L., Gao S., Hedrick J.L., Yang Y. Injectable hydrogels from triblock copolymers of vitamin E-functionalized polycarbonate and poly(ethylene glycol) for subcutaneous delivery of antibodies for cancer therapy. Adv. Funct. Mater. 2014, 24:1538-1550.
231. Nicolle E., Boccard J., Guilet D., Dijoux-Franca M.G., Zelefac F., Macalou S., et al. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur. J. Pharm. Sci. 2009, 38:39-46.
232. Zhao X., Kim J., Cezar C.A., Huebsch N., Lee K., Bouhadir K., et al. Active scaffolds for on-demand drug and cell delivery. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:67-72.
233. Kim J.W., Ho W.J., Wu B.M. The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res. 2011, 31:3237-3245.
234. Hongisto V., Jernstrom S., Fey V., Mpindi J.P., Kleivi Sahlberg K., Kallioniemi O., et al. High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells. PloS One 2013, 8:e77232.
235. Gillet J.P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18708-18713.
236. Ma L., Barker J., Zhou C., Li W., Zhang J., Lin B., et al. Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Biomaterials 2012, 33:4353-4361.
237. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell. 2010, 18:884-901.